March 21, 2012 /PRNewswire/ --
Vista Partners announced today that it has updated coverage on
ADVENTRX Pharmaceuticals, Inc.
(AMEX: ANX) ("The Company" or "ANX")
; and maintains its twelve month target price of
Ross Silver, Principal Analyst at Vista Partners stated, "The
GlycoMimetics deal with
Pfizer, as reported by
theflyonthewall.com, for their investigational compound GMI-1070 currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease has a potential value of approximately
$340M. This deal would seem to provide a benchmark for which to base value of ANX-188, which ADVENTRX has stated, will begin a Phase 3 trial in 2012." Mr. Silver continues "ANX currently trades at a negative enterprise value with its market cap currently being less than its cash balance. In addition, the cash value per share was approximately
$1.06 at 2011 year end, a discount of approximately 71% from the current share price. This would seem to indicate that the Company is currently being given little to no value for its two Phase 3 clinical candidates which could serve large markets: ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis; and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere."
To download a FREE copy of the ADVENTRX Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.